Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 500 million reported cases of COVID-19 worldwide with relatively high morbidity and mortality. Although global vaccination drive has helped control the pandemic, the newer variant of the virus still holds the world in ransom. Several medicinal herbs with antiviral properties have been reported, and one such promising herb is Nigella sativa (NS). Recent molecular docking, pre-clinical, and clinical studies have shown that NS extracts may have the potential to prevent the entry of coronaviruses into the host cell as well as to treat and manage COVID-19 symptoms. Several active compounds from NS, such as nigelledine, α-hederin, dithymoquinone (DTQ), and thymoquinone (TQ), have been proposed as excellent ligands to target angiotensin-converting enzyme 2 (ACE2 receptors) and other targets on host cells as well as the spike protein (S protein) on SARS-CoV-2. By binding to these target proteins, these ligands could potentially prevent the binding between ACE2 and S protein. Though several articles have been published on the promising therapeutic role of NS and its constituents against SARS-CoV-2 infection, in this review, we consolidate the published information on NS and SARS-CoV-2, focusing on pre-clinical in silico studies as well as clinical trials reported between 2012 and 2023.
Similar content being viewed by others
Data availability
“Several in vivo and human studies have reported that there are no significant adverse effects following NS administration, it is imperative to formally investigate and confirm the safety and the efficacy profile of NS extracts as a remedy for COVID-19” For this statement we referred to published studies on human and animal models which have shown that administration of NS produced no significant hepatic, renal, gastrointestinal adverse effects, or any other marked side effects other than few reported cases of allergic contact dermatitis. The toxicological and safety profile of NS has established it as a safe therapeutic herb, with a high lethal dosage 50 (LD50) value (Mashayekhi-Sardoo et al. 2020).
References
Aanouz I, Belhassan A, El-Khatabi K, Lakhlifi T, El-Ldrissi M, Bouachrine M (2021) Moroccan medicinal plants as inhibitors against SARS-CoV-2 main protease: computational investigations. J Biomol Struct Dyn 39:2971–2979
Abdallah HM, El-Halawany AM, Darwish KM, Algandaby MM, Mohamed GA, Ibrahim SRM et al (2022) Bio-guided isolation of SARS-CoV-2 main protease inhibitors from medicinal plants: in vitro assay and molecular dynamics. Plants Basel 11:1
Abidi A, Robbe A, Kourda N, Ben Khamsa S, Legrand A (2017) Nigella sativa, a traditional Tunisian herbal medicine, attenuates bleomycin-induced pulmonary fibrosis in a rat model. Biomed Pharmacother 90:626–637
Adamska A, Stefanowicz-Hajduk J, Ochocka JR (2019) Alpha-Hederin, the active saponin of Nigella sativa, as an anticancer agent inducing apoptosis in the SKOV-3 cell line. Molecules 24:1
Agagunduz D, Celik MN, Citar Daziroglu ME, Capasso R (2021) Emergent drug and nutrition interactions in COVID-19: a comprehensive narrative review. Nutrients 13:1
Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, Damanhouri ZA, Anwar F (2013) A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac J Trop Biomed 3:337–352
Ahmad A, Rehman MU, Ahmad P, Alkharfy KM (2020) Covid-19 and thymoquinone: Connecting the dots. Phytother Res 34:2786–2789
Ahmad A, Raish M, Alkharfy KM (2021a) The potential role of thymoquinone in preventing the cardiovascular complications of COVID-19. Vascul Pharmacol 141:106899
Ahmad I, Pawara R, Surana S, Patel H (2021b) The repurposed ACE2 inhibitors: SARS-CoV-2 entry blockers of covid-19. Top Curr Chem (cham) 379:40
Ahmad S, Abbasi HW, Shahid S, Gul S, Abbasi SW (2021c) Molecular docking, simulation and MM-PBSA studies of Nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment. J Biomol Struct Dyn 39:4225–4233
Akram Khan M, Afzal M (2016) Chemical composition of Nigella sativa Linn: Part 2 recent advances. Inflammopharmacology 24:67–79
Amin B, Hosseinzadeh H (2016) Black cumin (Nigella sativa) and its active constituent, thymoquinone: an overview on the analgesic and anti-inflammatory effects. Planta Med 82:8–16
Anand AV, Balamuralikrishnan B, Kaviya M, Bharathi K, Parithathvi A, Arun M et al (2021) Medicinal plants, phytochemicals, and herbs to combat viral pathogens including SARS-CoV-2. Molecules 26:1
Ashraf S, Ashraf S, Akmal R, Ashraf M, Kalsoom L, Maqsood A et al (2021) Prophylactic potential of honey and Nigella sativa L. against hospital and community-based SARS-CoV-2 spread: a structured summary of a study protocol for a randomised controlled trial. Trials 22:618
Badary OA, Hamza MS, Tikamdas R (2021) Thymoquinone: a promising natural compound with potential benefits for COVID-19 prevention and cure. Drug Des Devel Ther 15:1819–1833
Baig A, Srinivasan H (2022) SARS-CoV-2 inhibitors from Nigella sativa. Appl Biochem Biotechnol 194:1051–1090
Barakat EM, El Wakeel LM, Hagag RS (2013) Effects of Nigella sativa on outcome of hepatitis C in Egypt. World J Gastroenterol 19:2529–2536
Bargi R, Asgharzadeh F, Beheshti F, Hosseini M, Sadeghnia HR, Khazaei M (2017) The effects of thymoquinone on hippocampal cytokine level, brain oxidative stress status and memory deficits induced by lipopolysaccharide in rats. Cytokine 96:173–184
Bin Abdulrahman KA, Bamosa AO, Bukhari AI, Siddiqui IA, Arafa MA, Mohsin AA et al (2022) The effect of short treatment with Nigella sativa on symptoms, the cluster of differentiation (CD) profile, and inflammatory markers in mild COVID-19 patients: a randomized, double-blind controlled trial. Int J Environ Res Public Health 19:1
Bouchentouf S, Missoum N (2020) Identification of compounds from Nigella sativa as new potential inhibitors of 2019 novel coronasvirus (Covid-19): molecular docking study
Damiescu R, Lee DYW, Efferth T (2022) Can essential oils provide an alternative adjuvant therapy for COVID-19 infections and pain management at the same time? Pharmaceuticals (basel) 15:1
Dey D, Hossain R, Biswas P, Paul P, Islam MA, Ema TI et al (2022) Amentoflavone derivatives significantly act towards the main protease (3CL(PRO)/M(PRO)) of SARS-CoV-2: in silico admet profiling, molecular docking, molecular dynamics simulation, network pharmacology. Mol Divers 2022:1–15
Divya M, Vijayakumar S, Chen J, Vaseeharan B, Duran-Lara EF (2020) South Indian medicinal plants can combat deadly viruses along with COVID-19? A review. Microb Pathog 148:104277
Duru CE, Duru IA, Adegboyega AE (2021) In silico identification of compounds from Nigella sativa seed oil as potential inhibitors of SARS-CoV-2 targets. Bull Natl Res Cent 45:57
Esharkawy ER, Almalki F, Hadda TB (2022) In vitro potential antiviral SARS-CoV-19-activity of natural product thymohydroquinone and dithymoquinone from Nigella sativa. Bioorg Chem 120:105587
Faheem, Kumar BK, Sekhar K, Kunjiappan S, Jamalis J, Balana-Fouce R, Tekwani BL, Sankaranarayanan M (2020) Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. Bioorg Chem 104:104269
Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282:1–23
Forouzanfar F, Bazzaz BS, Hosseinzadeh H (2014) Black cumin (Nigella sativa) and its constituent (thymoquinone): a review on antimicrobial effects. Iran J Basic Med Sci 17:929–938
Gholamnezhad Z, Shakeri F, Saadat S, Ghorani V, Boskabady MH (2019) Clinical and experimental effects of Nigella sativa and its constituents on respiratory and allergic disorders. Avicenna J Phytomed 9:195–212
Gonzalez-Maldonado P, Alvarenga N, Burgos-Edwards A, Flores-Giubi ME, Barua JE, Romero-Rodriguez MC et al (2022) Screening of natural products inhibitors of SARS-CoV-2 entry. Molecules 27:1
Gunes AE, Gozeneli O, Akal AA, Guldur ME, Savik E (2017) Reduction of side effects of hyperbaric oxygen therapy with thymoquinone treatment in rats. Undersea Hyperb Med 44:337–343
Hadi V, Kheirouri S, Alizadeh M, Khabbazi A, Hosseini H (2016) Effects of Nigella sativa oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Avicenna J Phytomed 6:34–43
Hafez Ghoran S, El-Shazly M, Sekeroglu N, Kijjoa A (2021) Natural products from medicinal plants with anti-human coronavirus activities. Molecules 26:1
Hao DC, Ge GB, Xiao PG, Wang P, Yang L (2015) Drug metabolism and pharmacokinetic diversity of ranunculaceae medicinal compounds. Curr Drug Metab 16:294–321
He J, Liu S, Tan Q, Liu Z, Fu J, Li T et al (2022) Antiviral potential of small molecules cordycepin, thymoquinone, and N6, N6-dimethyladenosine targeting SARS-CoV-2 entry protein ADAM17. Molecules 27:1
Hilgenfeld R (2014) From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 281:4085–4096
Hosseinzadeh H, Parvardeh S (2004) Anticonvulsant effects of thymoquinone, the major constituent of Nigella sativa seeds, in mice. Phytomedicine 11:56–64
Hu B, Huang S, Yin L (2021) The cytokine storm and COVID-19. J Med Virol 93:250–256
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506
Hui DS, Memish ZA, Zumla A (2014) Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med 20:233–241
Ikhsan M, Hiedayati N, Maeyama K, Nurwidya F (2018) Nigella sativa as an anti-inflammatory agent in asthma. BMC Res Notes 11:744
Imran M, Khan SA, Abida, Alshammari MK, Alkhaldi SM, Alshammari FN et al (2022) Nigella sativa L. and COVID-19: a glance at the anti-COVID-19 chemical constituents, clinical trials, inventions, and patent literature. Molecules 27:1
Islam MN, Hossain KS, Sarker PP, Ferdous J, Hannan MA, Rahman MM, Chu DT, Uddin MJ (2021) Revisiting pharmacological potentials of Nigella sativa seed: a promising option for COVID-19 prevention and cure. Phytother Res 35:1329–1344
Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagata N (2019) TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol 93:1
Jackson CB, Farzan M, Chen B, Choe H (2022) Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23:3–20
Jakhmola Mani R, Sehgal N, Dogra N, Saxena S, Pande Katare D (2022) Deciphering underlying mechanism of Sars-CoV-2 infection in humans and revealing the therapeutic potential of bioactive constituents from Nigella sativa to combat COVID19: in-silico study. J Biomol Struct Dyn 40:2417–2429
Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT (2021) SARS-CoV-2, the pandemic coronavirus: molecular and structural insights. J Basic Microbiol 61:180–202
Kadil Y, Mouhcine M, Filali H (2021) In silico investigation of the SARS CoV2 protease with thymoquinone, the major constituent of Nigella sativa. Curr Drug Discov Technol 18:570–573
Keyhanmanesh R, Nazemiyeh H, Mazouchian H, Bagheri Asl MM, Karimi Shoar M, Alipour MR, Boskabady MH (2014) Nigella sativa pretreatment in guinea pigs exposed to cigarette smoke modulates in vitro tracheal responsiveness. Iran Red Crescent Med J 16:e10421
Khabbazi A, Javadivala Z, Seyedsadjadi N, Malek Mahdavi A (2020) A systematic review of the potential effects of Nigella sativa on rheumatoid arthritis. Planta Med 86:457–469
Khalifa SAM, Yosri N, El-Mallah MF, Ghonaim R, Guo Z, Musharraf SG et al (2021) Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic. Phytomedicine 85:153311
Khan MA (2019) Thymoquinone, a constituent of prophetic medicine-black seed, is a miracle therapeutic molecule against multiple diseases. Int J Health Sci (qassim) 13:1–2
Khan T, Khan MA, Mashwani ZU, Ullah N, Nadhman A (2021) Therapeutic potential of medicinal plants against COVID-19: the role of antiviral medicinal metabolites. Biocatal Agric Biotechnol 31:101890
Khan MT, Ali A, Wei X, Nadeem T, Muhammad S, Al-Sehemi AG, Wei D (2022) Inhibitory effect of thymoquinone from Nigella sativa against SARS-CoV-2 main protease. An in-Silico Study Braz J Biol 84:e250667
Khanna K, Kohli SK, Kaur R, Bhardwaj A, Bhardwaj V, Ohri P et al (2021) Herbal immune-boosters: substantial warriors of pandemic Covid-19 battle. Phytomedicine 85:153361
Khazdair MR, Ghafari S, Sadeghi M (2021) Possible therapeutic effects of Nigella sativa and its thymoquinone on COVID-19. Pharm Biol 59:696–703
Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA et al (2018) Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep 8:15701
Kirtipal N, Bharadwaj S, Kang SG (2020) From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect Genet Evol 85:104502
Kooti W, Hasanzadeh-Noohi Z, Sharafi-Ahvazi N, Asadi-Samani M, Ashtary-Larky D (2016) Phytochemistry, pharmacology, and therapeutic uses of black seed (Nigella sativa). Chin J Nat Med 14:732–745
Koshak DAE, Koshak PEA (2020) Nigella sativa L. as a potential phytotherapy for coronavirus disease 2019: a mini review of in silico studies. Curr Ther Res Clin Exp 93:100602
Koshak AE, Koshak EA, Mobeireek AF, Badawi MA, Wali SO, Malibary HM et al (2021) Nigella sativa for the treatment of COVID-19: an open-label randomized controlled clinical trial. Complement Ther Med 61:102769
Kulyar MF, Li R, Mehmood K, Waqas M, Li K, Li J (2021) Potential influence of Nagella sativa (Black cumin) in reinforcing immune system: a hope to decelerate the COVID-19 pandemic. Phytomedicine 85:153277
Kumar R, Nehul S, Singh A, Tomar S (2021) Identification and evaluation of antiviral potential of thymoquinone, a natural compound targeting Chikungunya virus capsid protein. Virology 561:36–46
Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J et al (2020) The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med 12:e12421
Maideen NMP (2020) Prophetic medicine-Nigella sativa (Black cumin seeds)—potential herb for COVID-19? J Pharmacopuncture 23:62–70
Maideen NMP, Balasubramanian R, Ramanathan S (2021) Nigella sativa (Black Seeds), a potential herb for the pharmacotherapeutic management of hypertension—a review. Curr Cardiol Rev 17:e230421187786
Maiti S, Banerjee A, Kanwar M (2021) In silico Nigellidine (N. sativa) bind to viral spike/active-sites of ACE1/2, AT1/2 to prevent COVID-19 induced vaso-tumult/vascular-damage/comorbidity. Vascul Pharmacol 138:106856
Maiti S, Banerjee A, Nazmeen A, Kanwar M, Das S (2022) Active-site molecular docking of nigellidine with nucleocapsid-NSP2-MPro of COVID-19 and to human IL1R-IL6R and strong antioxidant role of Nigella sativa in experimental rats. J Drug Target 30:511–521
Majdalawieh AF, Fayyad MW (2015) Immunomodulatory and anti-inflammatory action of Nigella sativa and thymoquinone: a comprehensive review. Int Immunopharmacol 28:295–304
Mani JS, Johnson JB, Steel JC, Broszczak DA, Neilsen PM, Walsh KB, Naiker M (2020) Natural product-derived phytochemicals as potential agents against coronaviruses: a review. Virus Res 284:197989
Mashayekhi-Sardoo H, Rezaee R, Karimi G (2020) Nigella sativa (black seed) safety: an overview. Asian Biomed (res Rev News) 14:127–137
Meng XY, Zhang HX, Mezei M, Cui M (2011) Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 7:146–157
Mir SA, Firoz A, Alaidarous M, Alshehri B, Bin Dukhyil AA, Banawas S et al (2022) Identification of SARS-CoV-2 RNA-dependent RNA polymerase inhibitors from the major phytochemicals of Nigella sativa: an in silico approach. Saudi J Biol Sci 29:394–401
Mollazadeh H, Afshari AR, Hosseinzadeh H (2017) Review on the potential therapeutic roles of Nigella sativa in the treatment of patients with cancer: involvement of apoptosis: black cumin and cancer. J Pharmacopuncture 20:158–172
Morse JS, Lalonde T, Xu S, Liu WR (2020) Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 21:730–738
Nallusamy S, Mannu J, Ravikumar C, Angamuthu K, Nathan B, Nachimuthu K et al (2021) Exploring phytochemicals of traditional medicinal plants exhibiting inhibitory activity against main protease, spike glycoprotein, RNA-dependent RNA polymerase and non-structural proteins of SARS-CoV-2 through virtual screening. Front Pharmacol 12:667704
Omar S, Bouziane I, Bouslama Z, Djemel A (2020) In-silico identification of potent inhibitors of COVID-19 main protease (Mpro) and angiotensin converting enzyme 2 (ACE2) from natural products: quercetin, hispidulin, and cirsimaritin exhibited better potential inhibition than hydroxy-chloroquine against COVID-19 main protease active site and ACE2
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L et al (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11:1620
Pakkir Maideen NM, Hassan Jumale A, Ramadan Barakat I, Khalifa Albasti A (2023) Potential of black seeds (Nigella sativa) in the management of long COVID or post-acute sequelae of COVID-19 (PASC) and persistent COVID-19 symptoms—an insight. Infect Disord Drug Targets 2023:1
Parida PK, Paul D, Chakravorty D (2020) The natural way forward: Molecular dynamics simulation analysis of phytochemicals from Indian medicinal plants as potential inhibitors of SARS-CoV-2 targets. Phytother Res 34:3420–3433
Pk M, Aa M, Panda PK (2023) Effects of active compounds of Nigella sativa in COVID-19: a narrative review. Recent Adv Antiinfect Drug Discov 2023:1
Pop RM, Trifa AP, Popolo A, Chedea VS, Militaru C, Bocsan IC, Buzoianu AD (2020) Nigella sativa: valuable perspective in the management of chronic diseases. Iran J Basic Med Sci 23:699–713
Ralph R, Lew J, Zeng T, Francis M, Xue B, Roux M et al (2020) 2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness. J Infect Dev Ctries 14:3–17
Rothan HA, Byrareddy SN (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 109:102433
Russo M, Moccia S, Spagnuolo C, Tedesco I, Russo GL (2020) Roles of flavonoids against coronavirus infection. Chem Biol Interact 328:109211
Said SA, Abdulbaset A, El-Kholy AA, Besckales O, Sabri NA (2022) The effect of Ni gella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: a randomized controlled clinical trial. Front Pharmacol 13:1011522
Salehi B, Quispe C, Imran M, Ul-Haq I, Zivkovic J, Abu-Reidah IM et al (2021) Nigella plants—traditional uses, bioactive phytoconstituents, preclinical and clinical studies. Front Pharmacol 12:625386
Setayesh M, Karimi M, Zargaran A, Abousaidi H, Shahesmaeili A, Amiri F, Hasheminasab FS (2022) Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): a randomized clinical trial. Integr Med Res 11:100869
Sharma S, Suvalka C, Bharti, Joshi M, Bahuguna A (2021) Potential inhibitors and plant based technology: an alternative approach to treat corona virus. Bioorg Chem 117:105460
Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ et al (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222
Shirvani H, Rostamkhani F, Arabzadeh E, Mohammadi F, Mohammadi F (2021) Potential role of Nigella sativa supplementation with physical activity in prophylaxis and treatment of COVID-19: a contemporary review. Sport Sci Health 17:849–854
Silva J, Figueiredo PLB, Byler KG, Setzer WN (2020) Essential oils as antiviral agents. Potential of essential oils to treat SARS-CoV-2 infection: an in-silico investigation. Int J Mol Sci 21:1
Soleymani S, Naghizadeh A, Karimi M, Zarei A, Mardi R, Kordafshari G, Esmaealzadeh N, Zargaran A (2022) COVID-19: general strategies for herbal therapies. J Evid Based Integr Med 27:2515690X211053641
Soy M, Keser G, Atagunduz P, Tabak F, Atagunduz I, Kayhan S (2020) Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 39:2085–2094
Srivastava N, Garg P, Srivastava P, Seth PK (2021) A molecular dynamics simulation study of the ACE2 receptor with screened natural inhibitors to identify novel drug candidate against COVID-19. PeerJ 9:e11171
Tahir Ul Qamar M, Alqahtani SM, Alamri MA, Chen LL (2020) Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 10:313–319
Tallei TE, Fatimawali, Niode NJ, Idroes R, Zidan B, Mitra S et al (2021) A comprehensive review of the potential use of green tea polyphenols in the management of COVID-19. Evid Based Complement Alternat Med 2021:7170736
Tavakkoli A, Mahdian V, Razavi BM, Hosseinzadeh H (2017) Review on clinical trials of black seed (Nigella sativa ) and its active constituent, thymoquinone. J Pharmacopuncture 20:179–193
Tayman C, Cekmez F, Kafa IM, Canpolat FE, Cetinkaya M, Tonbul A, Uysal S, Tunc T, Sarici SU (2013) Protective effects of Nigella sativa oil in hyperoxia-induced lung injury. Arch Bronconeumol 49:15–21
Taysi S, Algburi FS, Mohammed ZR, Ali OA, Taysi ME (2022) Thymoquinone: a review on its pharmacological importance, and its association with oxidative stress, COVID-19, and radiotherapy. Mini Rev Med Chem 22:1847–1875
Tortorici MA, Veesler D (2019) Structural insights into coronavirus entry. Adv Virus Res 105:93–116
Touret F, de Lamballerie X (2020) Of chloroquine and COVID-19. Antiviral Res 177:104762
Ullah S, Munir B, Al-Sehemi AG, Muhammad S, Haq IU, Aziz A, Ahmed B, Ghaffar A (2022) Identification of phytochemical inhibitors of SARS-CoV-2 protease 3CL(pro) from selected medicinal plants as per molecular docking, bond energies and amino acid binding energies. Saudi J Biol Sci 29:103274
van Montfort RLM, Workman P (2017) Structure-based drug design: aiming for a perfect fit. Essays Biochem 61:431–437
Velavan TP, Meyer CG (2020) The COVID-19 epidemic. Trop Med Int Health 25:278–280
Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B et al (2020) COVID-19: a promising cure for the global panic. Sci Total Environ 725:138277
Walls AC, Xiong X, Park YJ, Tortorici MA, Snijder J, Quispe J et al (2019) Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell 176:1026-1039 e15
Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM (2020) SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 10:587269
WHO (2022). WHO coronavirus (COVID-19) dashboard (Online). Available: https://covid19.who.int/. Accessed 30/6/2022
Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y et al (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 10:766–788
Xu J, Zhang Y (2020) Traditional Chinese medicine treatment of COVID-19. Complement Ther Clin Pract 39:101165
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8:420–422
Xu H, Liu B, Xiao Z, Zhou M, Ge L, Jia F et al (2021) Computational and experimental studies reveal that thymoquinone blocks the entry of coronaviruses into in vitro cells. Infect Dis Ther 10:483–494
Yadav R, Chaudhary JK, Jain N, Chaudhary PK, Khanra S, Dhamija P, Sharma A, Kumar A, Handu S (2021) Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells 10:1
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8:475–481
Zeyad Bazbouz L, Ghassan Ibrahim F, Lakshmi Chelakkot A, Matar R, Merheb M, Hodeify R, Vazhappilly CG (2023) Plant phytochemicals as potential candidates for treating post-COVID-19 lung infections. Phytother Res 37:383–387
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z et al (2020) The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 214:108393
Zhao Z, Li Y, Zhou L, Zhou X, Xie B, Zhang W, Sun J (2021) Prevention and treatment of COVID-19 using Traditional Chinese Medicine: a review. Phytomedicine 85:153308
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al (2020) A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382:727–733
Acknowledgements
The authors acknowledge the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) and Al Jalila Foundation, UAE
Funding
This study was in part supported by the Al Jalila Foundation (AJF) and the MBRU-Al Mahmeed Research Fund. ACC was supported by AJF Post-Doctoral Fellowship Research Award; NA and AP were supported by MBRU-Al Mahmeed Research Grant (ALM20-0075).
Author information
Authors and Affiliations
Contributions
Conceptualization: ACC, NA, and RR; Data acquisition and original draft preparation: ACC, NA, AP; Reviewing and editing: All authors; RR supervised the study.
Corresponding author
Ethics declarations
Conflict of interest
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cyril, A.C., Ali, N.M., Nelliyulla Parambath, A. et al. Nigella sativa and its chemical constituents: pre-clinical and clinical evidence for their potential anti-SARS-CoV-2 effects. Inflammopharmacol 32, 273–285 (2024). https://doi.org/10.1007/s10787-023-01385-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-023-01385-9